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Objectives: Dedifferentiated  chondrosarcoma  presents  a  very
dif￿ cult clinical problem. Long term survival is known to be poor,
but  a  large  clinical  series has  not  been analyzed  in  the  era of
modern diagnostic and treatment modalities.
Methods: A  retrospective chart  review  of  all  cases  of  patients
presenting with dedifferentiated chondrosarcoma at our institu-
tion from 1984–2000 was performed.This was done as an exten-
sion  to  a  study  published  in 1986 prior  to  the  era of  modern
chemotherapy.
Results: There were 42 cases in 25 men and 17 women of average
age 56 (range 24–83 years). MSTS grades at presentation were 5
IIA, 27 IIB, and 10 III.Three patients underwent biopsy only, 19
had limb sacri￿ cing, and 20 had limb sparing procedures; surgical
margins were intralesional in 3, marginal in 2, and wide in 20, and
radical in 14.Twenty-seven patients received adjuvant therapy (22
chemotherapy  only, 2 radiotherapy  only, 3  combined  therapy).
Median survival was 8 months; 5-year survival was 7.1%. There
was no statistical difference in survival between patients who did
and did not receive chemotherapy, had wide versus radical resec-
tion, or had limb sparing versus sacri￿ cing procedures.There were
no statistically signi￿ cant difference between patients treated prior
to 1986 and those subsequently.
Conclusions: Despite advances in diagnostic modalities, surgical
treatments, and adjuvant therapies, dedifferentiated chondrosar-
coma continues to carry a poor prognosis.The use of current adju-
vant  chemotherapy  and  its  inherent risks and  bene￿ ts  remains
questionable in this population.
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Objectives: To determine if amifostine given twice with each dose
of ifosfamide or cyclophosphamide could provide protection from
the myelotoxic effects of high dosage alkylator therapy,and prevent
delay in the administration of chemotherapy.
Methods: Patients less than 30 years of age with Ewing sarcoma
metastatic at diagnosis and normal organ function were enrolled
on  P9457, a  study  of  maximally  intensi￿ ed  alkylator  therapy
administered without  stem  cell support. Cycles included alter-
nating courses of ifosfamide, etoposide and vincristine, doxoru-
bicin  and  cyclophosphamide. Amifostine  was  given  to  a
randomized one-half of ____patients  entered in the last half of 
the study. The dosage administered was 825 mg/m2 15 minutes
prior to,and 3 hours after the beginning of each dose of ifosfamide
or  cyclophosphamide, with  premedications  and  precautions 
as  previously  described. Days  ANC  <500/ul, platelets 
>50,000/ul  and  between  cycles  were  analyzed  at  weeks  6, 12 
and 18 of therapy.
Results: There was no signi￿ cant difference seen in the arithmetic
mean number of days with platelet count < 50,000/ul: 31 with
amifostine, 30 without  amifostine  (Wilcoxon rank sum  test, p-
value: 0.38), the arithmetic mean number of days with absolute
neutrophil  count  <  500/ul: with  amifostine, 31  days, without
amifostine, 30 days (WRS, p = 0.14), or the number of days until
the next chemotherapy cycle: with amifostine: 30 days, without
amifostine, 29 days (p= 0.45)
Conclusions: In the dose and schedule used, amifostine did not
provide myeloprotection from the toxicity of high dose alkylator
therapy, and did not shorten the interval until the administration
of the next chemotherapy cycle.
Cd44s Is A Prognostic Marker In Soft Tissue Sarcoma
[Abstract ID: 23]
Category: Surgery
Authors: Matthias Peiper
1,Takeo Sato
1, Antje Heinecke
1, Claus
F. Eisenberger
1,Wolfram Trudo Knoefel
1, Jakob R. Izbicki
1
Author  Institutions: 1Department  of  Surgery  University  of
Hamburg, Germany Presenter: Matthias Peiper
peiper@uke.uni-hamburg.de
Correspondent: Matthias Peiper
peiper@uke.uni-hamburg.de
Hamburg Germany 20246
Ph: xx4949428032450
Fax: xx4940428033458
Objectives: The expression of CD44 has been identi￿ ed as prog-
nostic factor in several malignant diseases. However, only few data
exist  correlating  CD44  expression  in  soft  tissue  sarcoma  with
subsequent tumor progression or recurrence.The purpose of this
study was to investigate the clinical signi￿ cance of CD44s in adult
soft tissue sarcoma (STS).
Methods: Tumor specimens of 62 patients with STS were evalu-
ated regarding CD44s expression  using  immunohistochemistry.
The signi￿ cance of the proposed prognostic indicators was evalu-
ated in relation to survival and local recurrence.
Results: Of  62  analyzed  specimens, 49  tumors  were  CD44s
positive compared to 13 CD44s negative tumors. Kaplan-Meier
survival  analysis  indicated  signi￿ cantly  better  survival  among
patients whose tumor was CD44s positive (P = 0.015).Variables
predictive  of  longer  survival  included  resection  quality  (R0,
P < 0.01) and tumor size (T1,P = 0.02).CD44s expression corre-
lates with prognosis of soft tissue sarcomas.
Conclusions: CD44s  may  play  a  pathogenetic  role  in  tumor
progression Determining the expression of CD44s in primary STS
could be a valuable tool for selecting patients for further adjuvant
treatment. Nevertheless, radical resection at initial surgery plays
the pivotal role in soft tissue sarcoma treatment.
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Objectives: Irradiation of the growth plate during treatment of
extremity sarcomas in pediatric patients often leads to undesirable
late sequelae.Growth plate PTHrP has been reported to be down-
regulated following irradiation.The purpose of this project was to
test the hypotheses that PTHrP rebounds as part of the normal
response  following  growth  plate  irradiation  and  that  a  proven
radioprotectant may act to enhance this PTHrP response.
Methods: Sixty weanling 5 week Sprague-Dawley rats underwent
right knee irradiation with single fraction 17.5 Gy while the left leg
served as internal control. Twelve animals (half pretreated with
amifostine) were euthanized at each of 0.5, 1, 2, 3, and 4 weeks.
Immunohistochemical  staining  was performed and analyzed on
tissue specimens for 3 animals per group per time for PTHrP, Bcl-
2, Bax, caspase,TGF-beta and FGF-2.
Results: Irradiated  tissue  demonstrated  reduced  staining  for
PTHrP early, but by 2 weeks after irradiation there was a notable
return in PTHrP expression to at least control levels. This post-
irradiation PTHrP response was blunted rather than enhanced by
amifostine. Amifostine  showed  its  most  dramatic  effects  in
reducing Bax expression. Amifostine did not increase proliferative
cytokines.
Conclusions: The  observed  PTHrP  response  corresponds  to
improving growth plate morphology and growth rate, suggesting a
role for PTHrP in response to growth plate irradiation.Amifostine
appears to decrease apoptosis mediators.This suggests a potential
role for complementary radioprotectants that increase or maintain
the  post-irradiation  PTHrP  levels, such  as  pentoxifylline, as  a
means of maximizing growth plate recovery following irradiation.
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Objectives: To evaluate the outcome for giant cell tumor of bone
treated with radiation therapy, with or without surgical resection.
Methods: A retrospective review of 25 consecutive patients with
pathologically con￿ rmed giant cell tumor of bone receiving radia-
tion therapy.
Results: The  anatomic  distribution  of  lesions  was  as  follows:
cervical spine, 3; temporal bone, 1; thoracic or lumbar spine, 9;
sacrum, 8; iliac, 1; and one each in the humerus, radius, and 1st
metacarpal bone.Tumor size ranged from 2–20 cm (median, 9.5
cm).Twelve patients were referred with recurrent disease having
undergone  one  or  more  prior  surgical  resections  or  had  been
heavily  pretreated  using  chemo-embolization  with  subsequent
recurrence. Fourteen patients were treated for gross disease, the
remaining eleven were treated after gross total surgical resection.
The  dose for radiation was  46 Gy (range  25–65 Gy). Median
follow up was 8.8 years (0.67–34 years).The actuarial 5-year OS
and DFS were 91% and 58%, respectively. The actuarial 5-year
LC and DMFS rates were 62% and 81%, respectively. Univariate
analysis suggested that treatment for recurrent disease correlated
with an inferior DFS (33% vs. 83%, p=0.06), DMFS (64% vs.
100%, p=0.08), and LC rate (42% vs. 83%, p=0.08) at 5 years.
Additionally,there was an inferior OS rate in those patients treated
with radiation alone (80% vs. 100%, p=0.04).
Conclusions: Primary  GCT  of  bone  is  a  radiosensitive  tumor.
Radiation should be considered as an adjuvant to surgery or as an
alternative in cases where excision would result in signi￿ cant func-
tional de￿ cits.
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Objectives: Amifostine, a selective free-radical scavenger, is the
only previously documented drug to achieve radioprotection of the
growth plate, but its effect is incomplete.The aim of this pilot is
to determine if any of four novel radioprotectant drugs other than
amifostine can individually preserve the integrity of, or minimize
damage  to, physeal  longitudinal  growth  during  single  radiation
dose exposure in an animal model.
Methods: Eighty-four weanling male Sprague-Dawley rats were
randomized into 16 groups of 4–6 animals. All groups received
single 17.5 Gy radiation exposure to the right knee with the left
serving as control. Groups IA-C received pentoxifylline 50, 200,
and 300 mg/kg. Groups IIA-B received selenium selenite 1.5 and
5 mg/kg. Groups IIIA-E received IL-1b 5, 15, 50, 125, and 500
mcg/kg. Groups IVA-E received misoprostol 0.1, 0.5, 1, 0, and 5
mg/kg.Group V received irradiation alone.At 6 weeks femoral and
tibial lengths were measured and limb length percentage differ-
ences  calculated  between  irradiated  and  unirradiated  limbs.
ANOVA was employed with alpha 0.05.
Results: The radiation dose of 17.5 Gy caused a mean femoral
length  discrepancy  of  21.1%. Pentoxifylline  at  the  lowest dose
reduced mean femoral limb  discrepancy to 15.3% (p=0.0001).
Higher doses were less effective. IL-1beta at 15 mcg/kg reduced
femoral mean length discrepancy to 16.7% (p<0.0001). Selenium
S76 CTOS abstractsand misoprostol demonstrated dose-dependent effects,the highest
dose for each resulting in 17.2% discrepancy (p<0.03).
Conclusions: At  speci￿ c  doses, each  of  the  four  tested  drugs,
administered  prior  to  a  single  irradiation  dose, signi￿ cantly
reduced limb length discrepancy in our animal model.The magni-
tude of the reduction remains less than previously demonstrated
for amifostine. Combination studies are underway.
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Objectives: We  describe  three  tumorigenic  murine  cell  lines,
which  have  a  p53  de￿ cient  osteoblast-like  cell  as  a  common
precursor.
Methods: MMC2, p53-/-  osteoblast-like  cell line, was  innocu-
lated  subcutaneously  into  athymic  mice. Cells  isolated  from
tumors were cultured in vitro.These cells were assayed for growth
properties in vitro and tumorigenicity in nude mice . Expression
of osteoblast-related genes were examined by Northern blotting.
Results: Tumors developed in 3 out of 8 sites, and polyclonal cell
lines  were  established  from  each  tumor, and  designated  as
MMOS1, MMOS2  and  MMOS3. Expression  patterns  of  the
osteoblast-related genes were correlated well with the features of
the original tumors, ranging  from an osteoblastic osteosarcoma
(MMOS2)  to  tumors  with  scarce  or  no  osteoid  formation
(MMOS1 and MMOS3).Properties as malignant cells also varied
among the three cell lines. MMOS1, which showed the slowest
growth  in  a  low-serum  condition, developed  markedly  larger
tumors in vivo than the other two cell lines. MMOS3 showed the
fastest growth in a low-serum condition and produced the largest
number of colonies in soft agar, but did not develop lung metas-
tases, whereas MMOS1 and MMOS2 developed lung metastases
with a frequency of 30% and 50%. Because these three cell lines
have a common precursor,the heterogeneity among them is clearly
attributed to genetic alterations that took place during transfor-
mation process,and therefore these cell lines will be suitable mate-
rials to isolate the responsible genes.
In Vitro Transformation Of The Rb(-/-) Murine Osteoblast
[Abstract ID: 44]
Category: Medical Oncology
Authors: Takeshi  Okamoto
1, Hiroshi  Yamamoto
1, Tomoki
Aoyama
1,Koichi Nishijo
1,Takeharu Nakamata
1,Taisuke Hosaka
1,
Tomitaka Nakayama
1,Takashi Nakamura
1, Junya Toguchida
2
Author  Institutions: 1Department  of  Orthopaedic  Surgery
Kyoto University, Japan;
2Institiute for Frontier Medical Science
Kyoto University, Japan
Presenter:Takeshi Okamoto
tokmt@frontier.kyoto-u.ac.jp
Correspondent: Junya Toguchida
togjun@frontier.kyoto-u.ac.jp
Kyoto city Japan 606–8507
Ph: +81–75–751–4142
Fax: +81–75–751–4144
Objectives: Objective: It is well known  that the retinoblastoma
(Rb) gene plays an important role in the development of osteosar-
coma. Precise sequential events after the inactivation of the Rb
gene, however, remains  to  be  investigated. Here  we  have
performed in vitro transformation experiments using Rb-/- murine
osteoblasts as a starting material.
Methods: Rb-/- osteoblast-like cells were isolated from long bone
of neonatal chimeric mice composed of wild-type and Rb-/- cells,
and using the ALP activity as an osteoblast marker, one clonal cell
line (¢ RbOB1) was established.
Results: ¢ RbOB1 expressed several marker genes as osteoblast
(type  I  collagen, osteocalcin, and  cbfa1/runx2), and  showed
vigorous  growth  in  vitro, but  neither  anchorage-independent
growth nor in vivo tumorigenecity was observed.To inactivate the
p53 gene in the ¢ RbOB1, p53DD, the truncated dominant-nega-
tive form of human p53 gene, was introduced by the retrovirus
vector, and a clonal cell line expressing p53DD was established
(¢ RbOB1p53DD). Induction of p53 gene by actinomycin D was
observed  in  the  ¢ RbOB1, but  not  in  the  ¢ RbOB1p53DD,
suggesting  that  the  wild-type  p53  was  inhibited  in ¢ RbOB1
p53DD. However, neither anchorage-independent growth nor in
vivo  tumorigenecity  was  observed  in  the  {?}RbOB1p53DD.
Finally, transfection  of  the  oncogenic  H-ras  gene  endowed
¢ RbOB1p53DD with the activity as completely transformed cells,
but tumors developed in nude mice failed to form osteoid.
Conclusions: The inactivation of Rb and p53 in osteoblast wasn’t
enough for the development of osteosarcoma.Therefore, we still
missed the last piece to develop osteosarcomas from osteoblasts.
External Beam Radiation Is An Effective Adjuvant Therapy For
Clear Cell Sarcoma
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Objectives: Clear cell sarcoma (CCS) is a rare soft tissue sarcoma.
We sought to determine prognostic indicators and effective treat-
ment methods.
Methods: We  completed  a  retrospective  review  of  the
Massachusetts General Hospital and Children’s Hospital, Boston,
records identifying 21 patients.We completed a systematic review
of the English literature identifying 283 patients with clinical data
from 83 articles. The cumulative database was used to evaluate
patient demographics,prognostic factors,and the effect of external
beam radiation.
Results: Common locations were foot/ankle, 38.7 percent, knee,
12.4 percent, and wrist/hand, 12.4 percent. Common metastatic
CTOS abstracts S77sites were lymph nodes and the lung. Overall 5 year survival was
48.6 percent.Metastasis at presentation was a prognostic indicator
with 5 year survival  of  13 percent vs  55 percent (p  <0.0001).
Tumor size less than 5 cm was prognostic with 5 year survival rates
of 30 percent vs 67 percent (p < 0.0001). 15 patients received
external beam radiation  for their primary tumor. All  15 had a
surgical resection, were metastasis free at diagnosis, and did not
receive chemotherapy.These patients received an average of 59.9
Gy.A control group of 100 patients with no radiation therapy but
similar  demographics  (age, tumor  size, primary  tumor, and
metastatic  free  at  diagnosis)  and  treatment  (surgical  resection
without chemotherapy) was identi￿ ed.Fewer patients treated with
radiation developed metastasis (13 vs 43 % p < 0.05) or died from
disease (13 vs 43 % p< 0.05).
Conclusions: CCS tends to occur in young adults, in distal loca-
tions and metastasize to lymph nodes and lung.Tumor size equal
or greater than 5 cm and metastasis at diagnosis are poor prog-
nostic indicators. External beam radiation is an effective adjuvant
for primary CCS therapy.
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Objectives: Chondromodulin-1(ChM1)  is  a  glycoprotein  that
inhibits angiogenesis and the expression is restricted to cartilage
and  eye. In  cartilageous  tumors, the  expression  of  ChM1  was
observed only in benign lesions,suggesting the role of loss of ChM
expression during the malignant transformation (Hayami, et al.
FEBS  letter, 2001). No  information, so  far, has  demonstrated
concerning the expression of ChM1 in osteosarcomas (OS), and
here we report that some OS express the ChM1, which may relate
to the origin of tumor cells.
Methods: Using RT-PCR, the expression of mRNA of ChM1 in
26 cases of osteosarcoma tissues and 7 lines of osteosarcoma cell
lines were analyzed.
Results: The mRNA expression of the ChM1 was observed in 10
out of 26 OS, most of which were subclassi￿ ed as chondroblastic
OS. Among  seven  OS  cell lines, the  expression  of  ChM1  was
observed in two, one of which was established from a chondrob-
lastic OS.Tumors positive for the ChM1 expressed the type II and
IX collagen, and aggrecan genes, as well as the osteocalcin genes,
suggesting  the  bidirectional  differentiation  potential  of  these
tumor cells. Treatment of ChM1 negative OS cell lines with 5-
azadeoxy-cytidine induced the expression of the ChM1 gene in
two cell lines. Bisul￿ te sequencing demonstrated the methylated
CpG residues in the critical promoter lesion in these cell lines,
which were not methylated in human normal cartilage cells.
Conclusions: These data suggest that some OSs stem from the mes-
enchymal cells with bidirectional potential, and epigenetic mecha-
nisms may take a part in the process of cell fate determination.
Malignant Fibrous Histocytoma Of The Extremities And Trunk –
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Objectives: Malignant ￿ brous histiocytoma is the most common
subtype  of  soft  tissue  sarcoma. Detailed understanding  of  this
tumour type may lead to improved therapeutical strategies.
Methods: An institutional review was performed about all MFH
patients operated on between 1988 and 1998.
Results: Eighty-six- patients with histologically con￿ rmed MFH
(G1: n=8, G2: n=23, G3: n=55) were analysed. Local recurrence
was  36%  after  a  median  of  13  months. Distant  metastases
occurred in 29% of patients. After a mean follow-up of 5.5 years,
42 patients were alive without evidence of disease, median survival
time was 68 months at a cumulative 5-year survival rate of 65%.
Tumour size signi￿ cantly in￿ uenced disease free survival (T2 vs.
T1, P < 0.01, risk ratio [RR] 5.5), as did tumour depth (subfas-
cial tumours, P = < 0.01, RR 3.3), and presence of lymph nodes
(P = 0.02, RR 6.5). Positive microscopic margins and subfascial
tumours were associated with an increased local recurrence rate
(RR 5.7, P < 0.0001 and RR 3.5, P = 0.02, respectively).The only
multivariate risk factors of distant metastases were tumour depth,
in which patients with subfascial tumours fared worse (RR 4.0, P
< 0.01) and tumour grade (RR 5.5, P = 0.03).
Conclusions: We  conclude  that  aggressive  but  limb  preserving
resection of MFH should be performed at initial operation to mini-
mize risk of local recurrence;a strict follow-up especially of subfas-
cial tumours should be performed.
Proliferation  And  Apoptosis  Are  Independent  Prognostic
Parameters In Human Liposarcoma
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Objectives: As  an  adjunct  to  conventional  grading  in  human
liposarcomas, the possible prognostic value of the rate of tumor
cell apoptosis and proliferation was investigated.
Methods: 51 patients  (female  n=21, male  n=30)  with  liposar-
coma resected between 1988 and 2000 in our center were included
in this study. Tumors were localised in  the extremities (n=28),
retroperitoneum (n=20) and trunk (n=3). Tumor margins were
S78 CTOS abstractsfree (n=25) or showed  residual microscopic (n=25)  or macro-
scopic (n=1) disease.Multiple variables for each patient,including
age, sex, tumor size, grading and numbers of apoptotic and prolif-
erating  cells  were  determined. Immunocytochemistry  was
performed for semiquantitative analysis of representative paraf￿ n
embedded  tissue  sections. Monoclonal  antibodies  targeted  to
proliferating  cell  nuclear  antigen  and  apoptotic  nuclei  (Tunel-
assay) were utilised.The results were correlated with the postop-
erative course of these patients
Results: The median survival time was 10.2 years. Multivariate
analysis  revealed a  signi￿ cant  correlation between survival  and
grading, apoptosis and proliferation (p < 0.05 each).
Conclusions: These data indicate that in liposarcoma tumor cell
apoptosis and proliferation are in addition to conventional grading
of strong prognostic value in the assessment of disease- speci￿ c
survival.
Reconstruction With Scapular Endoprosthesis Provides Superior
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Comparison To Patients Without Endoprosthetic Reconstruction
[Abstract ID: 58]
Category: Surgery
Authors: Felasfa  M Wodajo
1, Jacob Bickels
2, James  C Wittig
3,
Kristen Kellar-Graney
1,Yehuda Kollender
2, Isaac Meller
2, Martin
M Malawer
1
Author Institutions: 1Washington Cancer Institute, DC, United
States;
2Tel Aviv Sourasky Medical Center, Israel;
3NYU Medical
Center Tisch Hospital, NY, United States
Presenter: Felasfa M Wodajo
felasfa@earthlink.net
Correspondent: Felasfa M Wodajo
felasfa@earthlink.net
Washington DC United States 20010
Ph: 202–877–7561
Fax: 202–877–8959
Objectives: Introduction
Suspension  of  the  humeral  head  from  the  clavicle  after  total
scapular resection is compared to endoprosthetic scapular recon-
struction.The surgical technique of endoprosthetic reconstruction
and functional results are described.
Patients: 23 patients with scapular tumors requiring total scapular
resection were treated.Resection included 12 total scapulectomies
and 11 en-bloc resections of the scapula and humeral head. Seven
patients  received endoprostheses. Four  had  prosthetic  humeral
heads suspended from the clavicle and 12 had suspension of the
native humeral head.All patients were followed more than 2 years.
Methods: Endoprosthetic  Surgical Technique  Patient  selection
was crucial. All peri-scapular muscles were tumor-free. Resection
was  usually  performed using  a  posterior approach. Most high-
grade scapula tumors were resected with the proximal humerus.
Smaller than a natural scapula,the prosthesis facilitated soft-tissue
reconstruction and was multiply fenestrated for myodesis. It was
placed on the serratus anterior and covered by the rhomboids,
trapezius and latissimus. A curved humeral head prosthesis was
cemented into the humerus and connected to the scapular pros-
thesis using Gore-tex™.
Results: There  were  no  deep  wound  infections, failures, or
secondary  amputations. Elbow  range-of-motion  and  hand
dexterity were similar. Patients with scapular endoprosthesis had
better active abduction (60 – 90 vs. 10 – 20). Patients with endo-
prosthetic reconstruction had a more natural contour. 6 patients
with  scapular  prostheses  (86%)  and  10  patients  with  humeral
suspensions (62%) had a good-to-excellent functional outcome.
Conclusions: Scapular  endoprosthesis  reconstruction  is  associ-
ated with better functional and cosmetic outcomes compared to
simple humeral head suspension from the clavicle.
In Vitro Chemosensitivity Of Human Soft Tissue Sarcoma Tissue
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Objectives: The Histoculture Drug Response Assay (HDRA) is
an in vitro chemosensitivity test that has a high correlation with
clinical response, the usefulness of which has  been reported in
various kinds of solid tumors. In this study, in order to investigate
the variation in chemosensitivity in STS, fresh biopsy or surgical
samples of STS were tested using the HDRA methods.
Methods: Eighty  samples  of  fresh  human  STS  were obtained
during either the biopsy or surgical removal at Keio University
Hospital in Japan between 1997 and 2001. As anti-tumor drugs,
cisplatin  (CDDP), doxorubicin  (ADM), pirarubicin  (THP), 4-
hydroxy-ifosfamide (4-H-IFO) and etoposide (VP-16) were used.
HDRA  was  performed  according  to  the  method  previously
reported.
Results: Drug  sensitivity  testing  by  HDRA  showed  that  two
drugs, ADM and THP, had a signi￿ cantly higher inhibitory rate
than CDDP, IFOS, or VP-16 in the eighty soft tissue sarcomas
tested. Depending  on  the  morphological  type, spindle  cell
sarcomas were sensitive to THP, which showed signi￿ cantly higher
inhibition  rates than CDDP, IFOS, or VP-16. Small round cell
sarcomas  were  relatively  sensitive  to  all  of  the  drugs  tested.
However the drug sensitivity of pleomorphic cell sarcoma was low
except for ADM and THP, while its sensitivity to THP was higher
than about 70%.
Conclusions: Depending on the morphological type, STS showed
various chemosensitivity in HDRA. However, there are numerous
other soft tissue sarcomas that do not belong to these categories;
drug sensitivity testing in each of them and the devising of indi-
vidualized  treatment strategies seems necessary to  improve  the
therapeutic outcome.
The Importance Of Tumour Volume To Distal Femoral Volume
Ratio In The Presentation Of Giant Cell Tumours Of The Distal
Femur
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Objectives: To identify the incidence of a cortical breech on the
initial presentation X-rays of patients with distal femoral GCTs,
and whether this lead to a higher rate of local recurrence of tumour
and increase in severity of surgery.
Methods: A prospective database is kept of all patients seen in the
unit, it contains data on over 10, 000 patients seen over 34 years.
Using the database initial presentation X-rays on 54 patients with
distal femoral GCTs were reviewed. The size of the tumour was
estimated using a facility of the database, by measuring the largest
dimensions of the tumour (depth, breadth & height).The volume
of  the  distal  femur  was  estimated  using  the  same  X-ray  and
CTOS abstracts S79computer programme.The X-rays were then carefully studied for
evidence of a cortical breach on antero-posterior (AP) and lateral
views.The records were also checked for evidence of subsequent
locally recurrent disease and subsequent surgery.
Results: X-rays  were  reviewed  on  54  patients  (29  male, 25
female), range of 18–72 years. All patients had a biopsy proven
GCT of the distal femur, X-rays (prior to biopsy) were reviewed.
34 (63%)  patients  with  a  cortical  breech on  X-ray. The  mean
tumour volume : distal femoral volumes (TV:DFV) was statisti-
cally greater between those patients with a cortical breach and
those without, using ANOVA (p<0.0001).There were 13 patients
with local recurrent disease but no statistical difference in subse-
quent local recurrence rates between the two patient groups.There
was also no statistical differences between the number of opera-
tions for those who presented with a cortical breach or without.
There was no evidence that more radical surgery was required if a
patient presented with a cortical breach.
Conclusions: The risk of cortical breech in patients with GCTs of
the distal femur is dependant upon the tumour volume to distal
femur volume ratio. If the ratio is above 54% then present with a
cortical  breech  on  X-ray  is  likely, (95%  con￿ dence  interval),
conversely if the ratio is less than 44 % then a cortical breach is
unlikely.There is no evidence those patients with a cortical breach
have a higher rate of local recurrence, an increased number of
operations or more radical surgery.
Low Local Recurrence Rate Of Large, Deep-seated, Soft-tissue
Sarcomas  With  Resection  After  Induction  (neoadjuvant)
Chemotherapy: histological Analysis Of Capsule Formation And
The Role Of adjuvant Radiotherapy
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Objectives: Surgical resection with “wide” margins  or a rim of
normal  tissue  is  the  mainstay  of  local  control  for  high-grade
extremity soft-tissue sarcomas.
Methods: From 1988–2002, 56 patients completed neoadjuvant/
adjuvant  a  chemotherapy  regimen  of  continuous  intravenous
doxorubucin, and  intra-arterial cisplatin and, after 1996, intra-
venous ifosfamide. No patient received preoperative radiotherapy.
LR analysis was performed on 42 patients and 23 patients were
used for analysis of “capsule” formation and development of a
classi￿ cation system. Type III indicated a well-developed ￿ brous
rim with inner/outer reactive zones, Type II implied interrupted
￿ brous zone and type I described no outer reactive zone and ill-
de￿ ned transition zone.
Results: Median follow-up was 55 months. LR was 12% (5/42).
Local control analysis  =  89.6%  (95%  CI: 74.7%  –  96.2%: 22
months) 89.6% (95% CI:67.1.8% –.97.3%: 55 months) DFS was
73.7% (95% CI: 60% – 83.9%) and 65.5% (95% CI: 47.3% –
80%).OS was 90.4% (95% CI:79% – 96%) and 84.8% (95% CI:
67.5% – 93.7%). Disease-speci￿ c OS was 90.4% (95% CI:78.9%
– 95.9%) and 86.8% (95% CI: 69.6% – 94.9%).Average necrosis
was  74%. Only  37.5%  (21/56)  received  adjuvant  radiation.
Average tumor size was 11.8 cm. 7/56 (12.5 %) reported minor
wound  complications. 25 (60%)  had reports specifying  margin
depth in centimeters. 21 (84%) reported </= margins speci￿ ed
had (60%) patients LR Most “tumor-free”. were remaining The
focally-present.tumor (4%) 25 1 and margin to the from 0.5-cm/=
0.5 cm. Type III capsule formation correlated to 94.3% average
necrosis (range 85%-99%),type II to 77% (range 50%-98%),type
I to 34% (range 10–50%).
Conclusions: Surgical margins are reported as being predictive of
local recurrence after soft-tissue sarcoma resection. Presence of
close or focally positive margins in this series did not correlate with
local recurrence.A well-formed ￿ brous “capsule”tumor periphery
and good chemotherapeutic response may contribute to improved
local control.
Gastrointestinal Stromal Tumour:The Patient Experience
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Objectives: The  management  of  patients  with  GIST  has  been
fundamentally altered by the introduction of Imatinib. Results in
advanced  disease have  shown  dramatic  results for a  previously
untreatable condition with little major toxicity.The experience of
patients may be complex and varied,including emotions stemming
from unexpected renewed health and uncertainty associated with
long term treatment with a new drug.The observations of a clin-
ical trial nurse have identi￿ ed particular patterns: a ￿ rst genera-
tion of patients diagnosed before Imatinib but who subsequently
bene￿ ted from it and a second generation offered treatment from
the time of diagnosis or relapse.
Methods: Illustrative case histories include 2 patients diagnosed
before  the  introduction  of  Imatinib  and  had  faced  a  terminal
illness and 2 patients referred at diagnosis or at relapse speci￿ cally
for Imatinib.
Results: Responses were partial remission in 2 and stable disease
in 2. Both  patients in the ￿ rst group  had a good  symptomatic
response with only grade 1–2 toxicities. One stated that any side
effect would be acceptable to achieve bene￿ t.The other resumed
full time work but remains anxious about how long the response
may last. In the second group, one patient had multiple grade 1–2
toxicities similar to those of her disease causing constant fears of
tumour re-growth. Another had no side effects but anxieties from
living with a cancer still in situ. All exhibited anxiety despite the
success of treatment.
Conclusions: Health professionals caring for patents with GIST
should recognise and acknowledge the additional issues faced by
patients which accompany response to Imatinib.
Gemcitabine And Docetaxel In Sarcoma
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Objectives: A  recent clinical trial of  the combination  of gemc-
itabine and docetaxel reported favorable results in patients with
unresectable, predominantly uterine leiomyosarcoma (LMS).The
objective of this report is to describe additional experience with
this combination in a variety of histologic subtypes of sarcoma.
Methods: A retrospective chart review of 24 consecutively treated
patients was performed.
Results: Twenty four patients with a median age of 52.5 years
(range 22–70) were treated with gemcitabine 675 mg/m2 on days
1 and 8 and docetaxel 100 mg/m2 on day 8 of a 21-day cycle.
Nineteen patients had previously received adriamycin, ifosfamide,
or both. Eighteen patients had metastatic disease, 4 had locally
recurrent disease, and  2  patients  presenting  with  their original
diagnosis were unable to receive adriamycin and/or ifosfamide for
medical  reasons. Patients  received  a  median  of  6  cycles  of
chemotherapy (range, 2–8 cycles); 5 continue on treatment at the
time of this report. Responses occurred in 6/10 LMS from various
primary sites, 2/2 angiosarcomas, 1/2 osteosarcomas, 1/2 malig-
nant peripheral nerve sheath tumors, 0/2 synovial sarcomas, 1/2
malignant  ￿ brous histiocytomas, 1/1 Ewing’s sarcoma, 1/1 high
grade sarcoma, not otherwise speci￿ ed, 0/1 chondrosarcoma, and
0/1 liposarcoma.We observed 5 complete responses and 8 partial
responses for an overall response rate of 54%. We are currently
con￿ rming these responses using the RECIST criteria.
Conclusions: The combination of gemcitabine with docetaxel is a
potentially  useful  therapy  for  a  variety  of  sarcomas. We  look
forward  to  participating  in  a  multicenter  clinical  trial  of  this
promising combination.
CTOS abstracts S81